Inaqovi
What Inaqovi is used for
Inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy. Inaqovi in combination with venetoclax is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Inaqovi
- Active substance
- cedazuridine;decitabine
- Disease area
- Leukemia, Myeloid
- Medicine group
- Antineoplastic agents
- ATC code
- L01BC58
- Marketing authorisation holder
- Otsuka Pharmaceutical Netherlands B.V.
- Authorised in the EU since
- 2023
Official information
In India
- Decitabine: 16 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Inaqovi used for?
Inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy. Inaqovi in combination with venetoclax is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.
What is the active substance in Inaqovi?
Inaqovi contains cedazuridine;decitabine.
Who makes Inaqovi?
The EU marketing authorisation holder is Otsuka Pharmaceutical Netherlands B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU